Pulmonx Corporation LUNG Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 75.5%+2.0pp | 74.2%+0.2pp | 73.3%-0.9pp | 73.1%-1.1pp | 73.5%-0.8pp | |
| Operating margin | -58.8%+7.2pp | -59.3%+9.6pp | -62.4%+11.0pp | -62.9%+14.5pp | -66%+16.3pp | |
| Net margin | -60.1%+5.2pp | -59.7%+7.6pp | -61.9%+10.1pp | -62.9%+12.7pp | -65.3%+15.2pp | |
| EBITDA margin | -57.7%+6.8pp | -58.1%+9.0pp | -61.2%+10.4pp | -61.5%+13.9pp | -64.5%+15.7pp | |
| Free cash flow margin | -33.2%+6.0pp | -36.3%+3.1pp | -35.5%+8.3pp | -35.3%+12.0pp | -39.2%+12.8pp | |
| Returns | ||||||
| Return on equity | -86.2%-25.5pp | -77.2%-21.9pp | -73.7%-21.7pp | -66.9%-17.7pp | -60.7%-14.5pp | |
| Return on assets | -39.3%-3.1pp | -37%-3.9pp | -37.1%-4.7pp | -35.6%-4.0pp | -36.2%-4.1pp | |
| Return on invested capital | -92.1%-22.2pp | -89.6%-25.3pp | -82.2%-22.7pp | -74.1%-14.9pp | -69.9%-8.5pp | |
| Efficiency | ||||||
| Asset turnover | 0.7×+0.1× | 0.6×+0.1× | 0.6×+0.1× | 0.6×+0.1× | 0.6×+0.2× | |
| Inventory turnover | 8.4×-3.6× | 8.8×-1.4× | 10.3×+3.2× | 11.6×+5.8× | 11.9×+6.8× | |
| Liquidity | ||||||
| Current ratio | 4.9×-0.1× | 5.1×-0.5× | 4.9×-2.8× | 5.3×-3.6× | 5×-2.0× | |
| Quick ratio | 4.7×-0.2× | 4.9×-0.6× | 4.8×-2.8× | 5.3×-3.6× | 4.9×-1.9× | |
| Cash ratio | 3.2×+0.7× | 3.4×+0.8× | 3.2×+0.2× | 3.2×-0.3× | 2.5×-0.2× | |
| Leverage | ||||||
| Debt-to-equity | 1.2×+0.5× | 1×+0.4× | 0.9×+0.3× | 0.8×+0.3× | 0.7×+0.4× | |
| Debt-to-assets | 0.5×+0.1× | 0.4×+0.1× | 0.4×+0.1× | 0.4×+0.1× | 0.4×+0.1× | |
| Interest coverage | -15.5×+1.4× | -17×-0.6× | -17.7×-1.4× | -17.2×-0.6× | -17×0.0× | |
| Per Share | ||||||
| Book value per share | $1.09-43.8% | $1.33-39.4% | $1.47-38.7% | $1.71-34.2% | $1.94-32.0% | |
| Valuation | ||||||
| Market capitalization | $54.91M-43.7% | $91.16M-66.0% | $66.01M-79.6% | $108.49M-55.7% | $267.83M-25.2% | |
| Enterprise value | $50.17M-39.2% | $78.81M-69.7% | $49.53M-84.7% | $93.01M-61.9% | $262.23M-23.1% | |
| Price / sales | 0.6×-0.5× | 1×-2.2× | 0.7×-3.4× | 1.2×-2.0× | 3.1×-1.8× | |
| Price / book | 1.3×-0.2× | 1.7×-1.4× | 1.1×-2.3× | 1.6×-0.9× | 3.4×+0.2× | |
| EV / sales | 0.6×-0.4× | 0.9×-2.2× | 0.5×-3.6× | 1×-2.2× | 3×-1.7× | |
| Free cash flow yield | -50.1%-19.4pp | -36%-23.7pp | -49.3%-38.6pp | -29.5%-14.7pp | -12.8%-2.2pp | |
| Earnings yield | -90.6%-36.0pp | -59.2%-38.2pp | -86%-68.3pp | -52.5%-28.9pp | -21.3%-4.9pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Pulmonx Corporation's profit margins?
- Pulmonx Corporation (LUNG) runs a 75.5% gross margin and a -58.8% operating margin, with a -60.1% net margin.
- Where do Pulmonx Corporation's ratios come from?
- Every ratio is computed from Pulmonx Corporation's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
